Abstract:Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the brain, which is by far the most prevalent form of dementia in adults over 65 years old. Amyloid β peptide (Aβ)-containing senile plaques are one of the neuropathological hallmarks of AD. The gradual accumulation of aggregated Aβ peptide initiates a complex multistep cascade, which include gliosis, inflammatory changes, oxidative stress, tangle formation (microtubule changes), neuritic/synaptic changes, and transmitter loss that finally lead to dementia. One of the strategies used to increase the clearance of Aβ peptide from the brain involves immunization with Aβ peptide 1–42 (Aβ1–42). However, clinical trials of active immunization were halted when patients in the study developed meningocephalitis. We have recently reported that semi-allogeneic somatic cell hybrids generated by the fusion of EL-4 T lymphoma cells (H-2b) and BALB/c-derived renal adenocarcinoma RAG cells (H-2d) can protect C57BL/6 mice (H-2b) challenged with a tumorigenic dose of EL-4 cells. The results of our studies are entirely consistent with the concept that the semi-allogeneic vaccine (made of RAG X EL-4 cell hybrids) induce a potent T cell-mediated (Th-1) response, that instructs T lymphocytes to kill autologous (EL-4) tumor cells. We have subsequently modified RAG X EL-4 cell hybrids to specifically target Aβ1–42. Ten-week-old female C57BL/6 APP transgenic mice (APPswe, PSEN1dE9) were treated with a single dose of modified RAG X EL-4 somatic cell hybrids, injected intraperitoneally (i.p.). At six months of age, all mice were sacrificed and their brains were fixed and sectioned to count the amyloid plaques. We observed that the brains of APP mice, treated with a single dose of the semi-allogeneic cell hybrids formulated with Aβ1–42, showed less numerous and smaller plaques compared to the brains of APP mice treated with Aβ1–42 in PBS or with unmodified RAG X EL-4 cell hybrids in PBS. The results of these preliminary animal studies led us to hypothesize that a T cell-mediated (Th-1) immune response targeting the Aβ1–42 will help clear this peptide from the brain, resulting in enhanced cognition, without the risk of adverse events such as meningocephalitis.

Improved Synaptic and Cognitive Function in Aged 3 × Tg-AD Mice with Reduced Amyloid-Β after Immunotherapy with a Novel Recombinant 6Aβ15-Tf Chimeric Vaccine.

Active Immunotherapy with 12-Mer Aβ1-42-like Assembly Vaccine Shows Efficacy in Aged 3×Tg-Ad Mice.

A Novel Aβ B-Cell Epitope Vaccine (rCV01) for Alzheimer’s Disease Improved Synaptic and Cognitive Functions in 3 × Tg-AD Mice

A Novel Recombinant 6Aβ15-Thc-c Chimeric Vaccine (rcv02) Mitigates Alzheimer’s Disease-Like Pathology, Cognitive Decline and Synaptic Loss in Aged 3 × Tg-AD Mice

Immunization with Aβ3-10-KLH vaccine improves cognitive function and ameliorates mitochondrial dysfunction and reduces Alzheimer’s disease-like pathology in Tg-APPswe/PSEN1dE9 mice

Strikingly Reduced Amyloid Burden And Improved Behavioral Performance In Alzheimer'S Disease Mice Immunized With Recombinant Chimeric Vaccines By Hexavalent Foldable A Beta(1-15) Fused To Toxin-Derived Carrier Proteins

Young blood plasma reduces Alzheimer’s disease-like brain pathologies and ameliorates cognitive impairment in 3×Tg-AD mice

Immunization with Aβ1-15 peptide vaccine improves learning and memory ability in AD transgenic model Tg2576 mice

Prevention of pathological change and cognitive degeneration of Tg2576 mice by inoculating Aβ 1–15 vaccine

A Multi-Targeting Immunotherapy Ameliorates Multiple Facets of Alzheimer’ S Disease in 3xtg Mice

A multi-targeting immunotherapy ameliorates multiple facets of Alzheimer's disease in 3xTg mice

Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer’s Disease Model Mice

DNA vaccines targeting amyloid-β oligomer ameliorate cognitive deficits of aged APP/PS1/tau triple-transgenic mouse models of Alzheimer’s disease

A pentavalent peptide vaccine elicits Aβ and tau antibodies with prophylactic activity in an Alzheimer's disease mouse model

Prophylactic immunotherapy of Alzheimer's disease using recombinant amyloid-β B-cell epitope chimeric protein as subunit vaccine

Efficacy of a Therapeutic Vaccine Using Mutated Β-Amyloid Sensitized Dendritic Cells in Alzheimer’s Mice

Intramembranous Fragment of Amyloid-β: A Potential Immunogen for Alzheimer’s Disease Immunotherapy

Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice

P2-315: A Novel Biotherapy for the Treatment of Alzheimer's Disease

Therapeutic Research of Intramembranous Fragment Vaccines of Amyloid-Β on APP Tg Mice

Vaccination of Alzheimer's Model Mice with Adenovirus Vector Containing Quadrivalent Foldable Aβ1–15 Reduces Aβ Burden and Behavioral Impairment Without Aβ-specific T Cell Response